Mājas>Klīniskā pētniecība>Klīniskie izmēģinājumi>RUSH2A

How to use the speech recognition tool?

NCT03146078

RUSH2A

Rate of Progression in USH2A Related Retinal Degeneration.

Type: Observational



Status of the trial: Active, Not recruiting

Orphan Drug Recognition: NA

Inclusion

  • Opening Date: 2017-08-01
  • Closing Date: 2021-12-31

Criteria

Inclusion: Participants with clinical diagnosis of rod-cone degeneration and at least 2 pathogenic or likely pathogenic mutations in USH2A gene; age ≥ 8 years

Exclusion: Mutations in genes that cause autosomal dominant RP, X-linked RP, or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than USH2A; Expected to enter experimental treatment trial at any time during this study; History

More information

Children: Yes

Adults: Yes

Funder Type: patient organisation


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: